+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Corporate Reputation of Pharma in 2018 - The Perspective of French Patient Groups

  • ID: 4969493
  • Report
  • November 2019
  • Region: France
  • 51 Pages
  • PatientView
1 of 4

FEATURED COMPANIES

  • Bayer
  • Boehringer Ingelheim
  • GSK
  • Janssen
  • MSD (Merck Sharp & Dohme)
  • Novartis
  • MORE

In this, the last of the 2018 series of reports about the corporate reputation of the pharmaceutical industry, we look at the views of 53 patient groups headquartered in France. This the 1st edition of 'The Corporate Reputation of Pharma, 2018 - from the Perspective of French Patient Groups'. For the sake of comparison, these 2018 French results also contain French results calculated from the previous year, 2017.

The 2018 results are drawn from a survey of patient groups worldwide, conducted November 2018-February 2019.

Profile of 2018's respondent French patient groups:

  • 53 French patient groups, of various specialties (7 of the patient groups focused on rare diseases.)
  • 17% of the respondent patient groups had an international geographic remit; 67% were national groups; 12% regional (an area within France); and 4% were local patient groups.
  • 57% of the French patient groups worked with one or more pharmaceutical companies.

Company analyses: The following 10 pharma companies were analysed by the 53 French patient groups for overall corporate reputation, and for performance at 12 individual indicators of corporate reputation: Bayer, Boehringer Ingelheim, GSK, Janssen, MSD (Merck Sharp & Dohme), Novartis, Pierre Fabre, Pfizer, Roche, and Sanofi.

Key Findings Across the Pharma Industry

  • 2018’s 53 respondent French patient groups were marginally more positive about the corporate reputation of the pharma industry as a whole than patient groups in most of the rest of the world. 43% of the French patient groups stated that the industry had an “Excellent” or “Good” corporate reputation in 2018, compared with 41% of patient groups worldwide saying the same.
  • However, the respondent French patient groups were significantly more negative than peer patient groups in other countries about the industry’s integrity, as well as about its ability to carry out a range of activities, including: providing high-quality products; be innovative, and supply high-quality patient information.
  • Feedback received from the respondent French patient groups points to several reasons behind these negative sentiments:
    • The industry’s lack of consistency at corporate reputation.
    • The industry’s lack of transparency. An autoimmune-disease patient group with a national remit commented “More transparency that we could report on would contribute to a better sense of trust. Secrecy suggests the presence of things to hide.”
    • A lack of good relations/communication. A national HIV/AIDS patient group thought that that companies limited their involvement with patient groups to recruiting patients for clinical trials, and it considered that they paid little attention to the issues faced by people on lifelong HIV treatments.
    • A failure to keep patients informed. A national endometriosis patient group referred to its need for information on a range of issues, including product safety; the limitations of drug treatments; and shortages in the supply of drugs.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer
  • Boehringer Ingelheim
  • GSK
  • Janssen
  • MSD (Merck Sharp & Dohme)
  • Novartis
  • MORE
  • Executive Summary
  • French Patient-Group Relationships With Pharma, 2018
  • Rankings Of 10 Pharma Companies, 2018 V. 2017 Among French Patient Groups Familiar With The Companies
  • Rankings Of 10 Pharma Companies, 2018 V. 2017 Among French Patient Groups That Work Or Partner With The Companies
  • Profiles Of The 10 Pharma Companies, 2018 V. 2017
  • Appendices
  • Appendix I: What The 53 French Patient Groups Say On Pharma, And How The Industry Can Improve

Tables and Charts

  • Percentage Of Respondent Patient Groups Stating That The Corporate Reputation Of The Pharmaceutical Industry As A Whole Was “Excellent” Or “Good”, 2018 - French Patient Groups V. Patient Groups Worldwide
  • The Rankings Of The Largest Multinational, Multi-Therapy Pharma Companies At Corporate Reputation (Among Respondent French Patient Groups Familiar With The Companies), 2018
  • Respondent French Patient Groups: Familiarity, And Partnerships, With Pharma Companies, 2018
  • The Types Of Relationships That Respondent French Patient Groups Have With Pharma Companies, 2018
  • The Corporate Reputation Of The Pharmaceutical Industry, 2018 - Compared With Eight Other Healthcare Sectors (According To Respondent French Patient Groups)
  • The Corporate Reputation Of The Pharmaceutical Industry, 2018 - France V. Global Percentage Of Respondent Patient Groups Stating “Excellent” Or “Good”
  • How Good Or Bad The Pharmaceutical Industry Was In 2018 At Carrying Out Specific Activities, According To Respondent French Patient Groups  
  • How Good Or Bad The Pharmaceutical Industry Was In 2018 At Carrying Out Specific Activities: Percentage Of Respondent French Patient Groups Stating “Excellent” Or “Good” V. Respondent Patient Groups Worldwide
  • Rankings Of Individual Pharma Companies, 2018 V. 2017, According To Respondent French Patient Groups Familiar With The Company
  • Rankings Of Individual Pharma Companies, 2018 V. 2017, According To Respondent French Patient Groups That Work Or Partner With The Company
  • Profiles Of The 10 Companies, 2018

Charts And Tables For Each Of The 10 Companies:

  • Number Of Respondent French Patient Groups Claiming Familiarity With The Company, 2018.
  • Number Of Respondent French Patient Groups Saying That They Had A Working Relationship With The Company, 2018.
  • Profile Of Respondent French Patient Groups Familiar, And Working, With The Company, 2018: Specialties; Geographic Remit; And Types Of Relationships.
  • Company Scores Among Respondent French Patient Groups Familiar With The Company, And Which Worked Or Partnered With The Company, For Each Of The 12 Indicators Of Corporate Reputation, 2018.
  • Percentage Of The Respondent French Patient Groups That Worked Or Partnered With The Company, But Which Also Worked With Other Companies, 2018.
  • Snapshot View: Where The Company Sits In The Tiers For Each Of The 12 Indicators Of Corporate Reputation (In The Higher, The Middle, Or The Lower Tier), As Assessed By Respondent French Patient Groups Familiar With The Company, 2018.
  • Overall Rankings For The Company, According To Respondent French Patient Groups Familiar With The Company, 2018 V. 2017.
  • Overall Rankings For The Company, According To Respondent French Patient Groups That Work Or Partner With The Company, 2018 V. 2017.
  • The Company’S Overall Patient Corporate Reputation Index (Pcri), 2018 V. 2017.
  • Company Rankings For Each Of The 12 Indicators, According To Respondent French Patient Groups Familiar, Or Working, With The Company, 2018 V. 2017.

Company Profiles

  • Bayer
  • Boehringer Ingelheim
  • GSK
  • Janssen
  • MSD (Merck Sharp & Dohme)
  • Novartis
  • Pierre Fabre
  • Pfizer
  • Roche
  • Sanofi
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bayer
  • Boehringer Ingelheim
  • GSK
  • Janssen
  • MSD (Merck Sharp & Dohme)
  • Novartis
  • Pierre Fabre
  • Pfizer
  • Roche
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll